Physician profile

James C Matchison

Interventional Cardiology · Torrance, CA

NPI 1629275631

$33,339.91

in general payments reported to CMS, 2019-2025

35 companies · $2,340 in 2025

The $2,340 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,053.66
Honoraria$2,750.00
Travel and Lodging$257.48

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Edwards Lifesciences Corporation $16,447.89 2019-2025 Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv)
Abiomed $7,268.29 2019-2025 Impella
Boston Scientific Corporation $2,413.06 2019-2025 Avvigo Guidance System, General - Balloon Catheters, Crossboss
Shockwave Medical, INC $1,645.99 2021-2025 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Philips North America LLC $918.99 2019-2023
Medtronic, INC. $582.95 2021-2023 Linq II, Micra, Corevalve Evolut R
Novartis Pharmaceuticals Corporation $497.46 2019-2025
Abbott Laboratories $472.98 2020-2025 Xience Skypoint, Dragonfly Opstar, Navitor
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $419.65 2019-2025 Lifevest
E.R. Squibb & Sons, L.L.C. $414.62 2019-2025 Camzyos, Eliquis
Janssen Pharmaceuticals, INC $376.60 2019-2024 Xarelto
Pfizer INC. $371.62 2019-2025
Medtronic Vascular, INC. $276.98 2019-2020
Livanova USA, INC. $191.80 2022
Astellas Pharma US INC $112.89 2020-2022
Show all 35 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $112.85 2019-2025 Repatha, Repatha
Cardiva Medical, INC. $109.11 2023-2024 Cardiva Vascade Mvp Vvcs 6-12f, Savvywire
Terumo Medical Corporation $99.05 2022
Teleflex LLC $84.72 2019-2024 Guideliner
Kestra Medical Technology Services, INC. $63.88 2023-2025 Assure Wcd
Novo Nordisk INC $57.26 2021-2022
Scpharmaceuticals INC. $49.76 2025
Astrazeneca Pharmaceuticals LP $49.68 2019-2023 Farxiga
Regeneron Healthcare Solutions, INC. $34.99 2019
Sanofi-Aventis U.S. LLC $31.28 2019
Ionis Pharmaceuticals, INC. $30.66 2025 Tryngolza
Bridgebio Pharma, INC. $30.32 2025 Attruby
Glaxosmithkline, LLC. $29.12 2025 Shingrix, Arexvy
Inspire Medical Systems, INC. $26.83 2025 Inspire
Acist Medical Systems, INC. $23.00 2021
Merck Sharp & Dohme LLC $21.93 2023 Verquvo
Cardiovascular Systems INC. $20.00 2023 Diamondback Coronary
Actelion Pharmaceuticals US, INC. $19.83 2019
Chiesi USA, INC. $17.41 2022
Boehringer Ingelheim Pharmaceuticals, INC. $16.46 2024 Jardiance

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James C Matchison

$33,339.91

in general payments reported 2019-2025

Years
2019-2025
Top company
Edwards Lifesciences Corporation
Context
The $2,340 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/409310/james-c-matchison

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.